Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CAO Sells $3,424,031.80 in Stock

Key Points

• Kiniksa’s chief accounting officer Michael Megna sold 36,260 shares for approximately $3.42 million at an average price of $94.43. The sale, made under a pre-arranged Rule 10b5-1 plan, reduced his holdings by 74.06% to 12,697 shares.
• Kiniksa reported quarterly EPS of $0.56, beating the $0.37 consensus, while revenue of $285.97 million topped analyst estimates of $260.66 million.
• Analysts hold a “Moderate Buy” consensus, with an average price target of $100.57; shares recently traded at $93.29.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CAO Michael Megna sold 36,260 shares of the stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $94.43, for a total transaction of $3,424,031.80. Following the sale, the chief accounting officer owned 12,697 shares in the company, valued at $1,198,977.71. This represents a 74.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Price Performance

KNSA traded up $2.49 during trading on Tuesday, hitting $93.29. 1,021,631 shares of the stock traded hands, compared to its average volume of 705,858. The business has a 50 day moving average price of $79.39 and a 200 day moving average price of $60.29. Kiniksa Pharmaceuticals International, plc has a twelve month low of $37.02 and a twelve month high of $98.48. The company has a market cap of $7.28 billion, a price-to-earnings ratio of 71.76 and a beta of 0.04.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. The company had revenue of $285.97 million for the quarter, compared to analyst estimates of $260.66 million. On average, equities research analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.26 earnings per share for the current year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors and hedge funds have recently bought and sold shares of KNSA. Allworth Financial LP boosted its stake in shares of Kiniksa Pharmaceuticals International by 42.0% during the second quarter. Allworth Financial LP now owns 453 shares of the company's stock valued at $29,000 after purchasing an additional 134 shares in the last quarter. Arizona State Retirement System raised its holdings in Kiniksa Pharmaceuticals International by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 10,132 shares of the company's stock valued at $648,000 after buying an additional 209 shares during the last quarter. GAMMA Investing LLC raised its holdings in Kiniksa Pharmaceuticals International by 21.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,278 shares of the company's stock valued at $95,000 after buying an additional 223 shares during the last quarter. Commonwealth Equity Services LLC boosted its position in Kiniksa Pharmaceuticals International by 2.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 10,871 shares of the company's stock worth $811,000 after buying an additional 237 shares during the period. Finally, First Trust Advisors LP boosted its position in Kiniksa Pharmaceuticals International by 3.1% during the 1st quarter. First Trust Advisors LP now owns 9,876 shares of the company's stock worth $476,000 after buying an additional 293 shares during the period. Institutional investors and hedge funds own 53.95% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. JPMorgan Chase & Co. boosted their target price on Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the stock an "overweight" rating in a research note on Friday. The Goldman Sachs Group lifted their price target on shares of Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a "buy" rating in a report on Wednesday, October 28th. Wedbush upped their price objective on shares of Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 28th. Wells Fargo & Company increased their price objective on shares of Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the company an "overweight" rating in a research note on Wednesday, October 28th. Finally, Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research report on Sunday, July 12th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Kiniksa Pharmaceuticals International currently has an average rating of "Moderate Buy" and a consensus price target of $100.57.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company's research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa's principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.